Other endpoints reported in the study included cholesterol measurements and sexual side effects:
- Dutasteride treatment was associated with a significant increase in LDL cholesterol, but not HDL cholesterol levels, according to investigators.
- The tamsulosin group also experienced an increase in LDL cholesterol, but in contrast to the dutasteride group, also had an increase in HDL cholesterol.
- As expected based on previously published reports, dutasteride was also associated with reduced total testosterone plasma levels, increased score on the Aging Males' Symptoms (AMS) scale, and increased erectile dysfunction as compared with tamsulosin.
Limitations of the analysis, Dr. Traish acknowledged, include its retrospective nature, the lack of a control group, and some imbalances in patient characteristics. Notably, the tamsulosin group had a significantly larger mean waist circumference, higher body weight, and elevated LDL and HDL values compared with the dutasteride group. The tamsulosin group also had a lower mean AMS score at baseline.
However, Dr. Traish said he hopes that these results will spark further interest from clinical collaborators who would like to undertake further research.
“By putting this paper out,” he said, “I’m trying to provoke myself, as well as my colleagues in the clinical and research community, to say, ‘let’s take a serious look at this.’ ”
More from Urology Times:
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.